1. Weihofen A, Liu Y, Arndt JW, Huy C, Quan C, Smith BA, et al. Development of an aggregate-selective, human-derived α-synuclein antibody BIIB054 that ameliorates disease
phenotypes in Parkinson’s disease models. Neurobiol Dis2019;124:276-88. doi:10.1016/j.nbd.2018.10.016
2. Fereshtehnejad SM, Shafieesabet M, Rahmani A, Delbari A, Lökk J. Medium-to-high prevalence of screening-detected parkinsonism in the urban area of Tehran, Iran: data from a
community-based door-to-door study. Neuropsychiatr Dis Treat 2015;11:321-32. doi:10.2147/ndt.S77391
3. Ho CY, Troncoso JC, Knox D, Stark W, Eberhart CG. Betaamyloid, phospho-tau and alpha-synuclein deposits similar to those in the brain are not identified in the eyes of Alzheimer’s
and Parkinson’s disease patients. Brain Pathol 2014;24(1):25-32. doi:10.1111/bpa.12070 

4. Sveinbjornsdottir S. The clinical symptoms of Parkinson’s disease. J Neurochem 2016;139 Suppl 1:318-24. doi:10.1111/jnc.13691
5. Crowley EK, Nolan YM, Sullivan AM. Exercise as a therapeutic intervention for motor and non-motor symptoms in Parkinson’s disease: evidence from rodent models. Prog Neurobiol
2019;172:2-22. doi:10.1016/j.pneurobio.2018.11.003
6. Berg D, Postuma RB, Adler CH, Bloem BR, Chan P, Dubois B, et al. MDS research criteria for prodromal Parkinson’s disease. Mov Disord 2015;30(12):1600-11. doi:10.1002/mds.26431
7. Keezer MR, Wolfson C, Postuma RB. Age, gender, comorbidity, and the MDS-UPDRS: results from a populationbased study. Neuroepidemiology 2016;46(3):222-7.doi:10.1159/000444021
8. Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al. Movement disorder society-sponsored revision of the unified Parkinson’s disease rating scale (MDSUPDRS):
scale presentation and clinimetric testing results. Mov Disord 2008;23(15):2129-70. doi:10.1002/mds.22340
9. Herrera CR, Beltramini GC, Avelar WM, Lima FO, Li LM. Cerebral vasomotor reactivity assessment using transcranial Doppler and MRI with apnea test. Braz J Med Biol Res 2016;49(11):e5437. doi:10.1590/1414-431x20165437
10. Alwatban M, Murman DL, Bashford G. Cerebrovascular Reactivity Impairment in Preclinical Alzheimer’s Disease. J Neuroimaging 2019;29(4):493–8. doi:10.1111/jon.12606
11. Sur S, Lin Z, Li Y, Yasar S, Rosenberg P, Moghekar A, et al. Association of cerebrovascular reactivity and Alzheimer pathologic markers with cognitive performance. Neurology 2020;95(8):e962-72. doi:10.1212/wnl.0000000000010133
12. Smoliński Ł, Członkowska A. Cerebral vasomotor reactivity in neurodegenerative diseases. Neurol Neurochir Pol 2016;50(6):455-62. doi:10.1016/j.pjnns.2016.07.011
13. Li H, Shao X, Jia J, Wang B, Wang J, Liu K, et al. A multimodal study on cerebrovascular dysfunction in cognitive decline of de novo Parkinson’s disease. Neuroimage Clin 2025;48:103836. doi:10.1016/j.nicl.2025.103836
14. Pelizzari L, Laganà MM, Rossetto F, Bergsland N, Galli M, Baselli G, et al. Cerebral blood flow and cerebrovascular reactivity correlate with severity of motor symptoms in Parkinson’s
disease. Ther Adv Neurol Disord 2019;12:1756286419838354. doi:10.1177/1756286419838354
15. Marsili L, Rizzo G, Colosimo C. Diagnostic criteria for Parkinson’s disease: from James Parkinson to the concept of prodromal disease. Front Neurol 2018;9:156. doi:10.3389/fneur.2018.00156
16. Ojeda AE, Martinez HR, Rivera FG, Garza JE, Medina HC, Davila SS. Cerebral vasoreactivity in Parkinson’s disease: a cross-sectional pilot study in a Hispanic cohort. J Alzheimers
Dis Parkinsonism 2017;7(3):336. doi:10.4172/2161-0460.1000336
17. Hamziee-Moghadam A, Iranmanesh F, Arabpour-Fathabadi A, Mohammadi F. Cerebrovascular reactivity and carotid intimamedia thickness in opium dependents: a case-control study. Addict Health 2018;10(2):131-6. doi:10.22122/ahj.v10i2.555
18. Camargo CH, Martins EA, Lange MC, Hoffmann HA, Luciano JJ, Young Blood MR, et al. Abnormal cerebrovascular reactivity in patients with Parkinson’s disease. Parkinsons Dis 2015;2015:523041. doi:10.1155/2015/523041
19. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 2010;25(15):2649-53.
doi:10.1002/mds.23429
20. Zamani B, Mehrabani M, Fereshtehnejad SM, Rohani M. Evaluation of cerebral vasomotor reactivity in Parkinson’s disease: is there any association with orthostatic hypotension?
Clin Neurol Neurosurg 2011;113(5):368-72. doi:10.1016/j.clineuro.2010.12.014
21. Hanby MF, Panerai RB, Robinson TG, Haunton VJ. Is cerebral vasomotor reactivity impaired in Parkinson disease? Clin Auton Res 2017;27(2):107-11. doi:10.1007/s10286-017-0406-x
22. Gurevich T, Gur AY, Bornstein NM, Giladi N, Korczyn AD. Cerebral vasomotor reactivity in Parkinson’s disease, multiple system atrophy and pure autonomic failure. J Neurol Sci
2006;243(1-2):57-60. doi:10.1016/j.jns.2005.11.028
23. Rubino A, Romeo T, Di Battista ME, Valente M, Papi C, Giacomini P, et al. Cognitive impairment in Parkinsondisease is associated with reduced cerebrovascular reactivity.Parkinsonism Relat Disord 2016;22:e59. doi:10.1016/j.parkreldis.2015.10.126
24. Muñoz A, Garrido-Gil P, Dominguez-Meijide A, Labandeira-Garcia JL. Angiotensin type 1 receptor blockage reduces L-DOPA-induced dyskinesia in the 6-OHDA model of Parkinson’s disease. Involvement of vascular endothelial growth factor and interleukin-1β. Exp Neurol 2014;261:720-32. doi:10.1016/j.expneurol.2014.08.019
25. Braak H, Rüb U, Gai WP, Del Tredici K. Idiopathic Parkinson’s disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen.
J Neural Transm (Vienna) 2003;110(5):517-36. doi:10.1007/s00702-002-0808-2
26. Al-Bachari S, Parkes LM, Vidyasagar R, Hanby MF, Tharaken V, Leroi I, et al. Arterial spin labelling reveals prolonged arterial arrival time in idiopathic Parkinson’s disease. Neuroimage
Clin 2014;6:1-8. doi:10.1016/j.nicl.2014.07.014
27. Bouhaddi M, Vuillier F, Fortrat JO, Cappelle S, Henriet MT, Rumbach L, et al. Impaired cardiovascular autonomic control in newly and long-term-treated patients with Parkinson’s
disease: involvement of L-DOPA therapy. Auton Neurosci 2004;116(1-2):30-8. doi:10.1016/j.autneu.2004.06.009